Recce’s New Classes of Synthetic Anti-infectives are designed to address the urgent global health threat posed by antibiotic resistant superbugs and emerging viral pathogens. Recce Pharmaceuticals have developed two primary drug candidates: RECCE® 327 for bacterial infections and RECCE® 529 for viral infections. RECCE® 529 is a new synthetic polymer formulation with indication against viruses. All RECCE® compounds are 100% water soluble at all pH levels in their liquid form. Recce Pharmaceuticals continues to strengthen and expand their product pipeline in order to find a treatment for ‘difficult to treat’ bacterial and viral infections.

RECCE® 327 - Bacterial Infections

There is a historic lack of innovation in the antibiotic drug development field to address this growing need for effective antibiotics. RECCE® 327 is one of the first new classes of antibiotics in over 30 years with a universal mechanism of action that allow its compounds to continuously kill bacteria and multi-drug resistant superbugs.

What Bacteria has RECCE® 327 demonstrated capability against?

  • bacteria 1 1 Clostridium difficile
  • bacteria 2 2 Helicobacter pylori
  • bacteria3 Pseudomonas aeruginosa
  • bacteria 3 3 Neisseria gonorrhoeae
  • bacteria5 Escherichia coli
  • bacteria6 Klebsiella pneumoniae
  • bacteria9 Staphylococcus aureus
  • bacteria9 Streptococcus pyogenes
  • bacteria9 Enterococcus species

RECCE® 529 – Viral Infections

In response to the pandemic outbreak of COVID-19 with no proven vaccine or therapeutics currently available, the Company is undertaking initial studies of RECCE 529 to indicate any potential therapeutic effect against SARS-CoV-2 (the virus causing the disease ‘Coronavirus’ or ‘COVID-19’).

Designed with a purpose

We have established a patented, automated, economical manufacturing process for our synthetic compounds. We have invested in a purpose built, wholly owned manufacturing facility, produced to the highest pharmaceutical standards.

Furthermore, the manufacturing process is reproducible and has a CMC (Chemistry, Manufacturing, and Controls) data package, essential for clinical study materials.

Recce Pharmaceutical’s synthetic process is efficient giving rise to a 99.9% product yield in several hours. It requires no specialised and expensive waste removal or risk of environmental contamination.

product overview

RECCE® – Multiple Anti-Infective Applications

Recce's technology enjoys the added opportunity of multiple markets and product categories.





pre clinical






product overview
Intravenous Administration Phase I IV study subjects screened in Q1 2020
  • Severe Sepsis — Blood poisoning
  • Pre Sepsis — Kidney and UTI infections
product overview
Topical Administration Phase I/II topical study HREC approved
  • Skin and Skin Structure Infection — Wound Infection, Contraction
product overview
Viral Indications COVID-19 testing national and international scientific facilities
  • R327 Prority 1 Candidate Group- Australian SARS-CoV-2 Anti-viral Program
  • R327 & R529 at Mutiple US Scientific Research Institutions testing against SARS-Cov-2
  • Influenza A and other Significant respiratory infections  
product overview
Other Indications New R435 to be tested against  H. pylori with Murdoch Children's Research Institute
  • Helicobacter pylori (H. pylori )-Leading Cause of Stomach Ulcers

There have been no new classes of antibiotics on the market for over 30 years - Recce® 327 has the potential to break that mould. Recce® 327 is a synthetic polymer, designed to target bacteria that cause infectious disease – including ones that are resistant to current antibiotics – the superbugs. Bacterial infections of the blood are deadly and affect an estimated 30 million people world-wide every year - this is where Recce® 327 is designed to act. Recce® 327 is designed to be administered through injection so it can quickly spread through the blood stream.

Recce® 327 is designed to adhere to the outer cell wall of the infectious bacteria through hydrophobic interactions. This weakens the cell wall and internal pressures from within the cell cause the bacteria to burst. The body’s own mechanisms can then clear the infection. Normal non-bacterial cells remain intact as they do not contain high internal pressures.

Tests have shown Recce® 327 is fast acting and as a broad spectrum antibiotic is effective against gram positive and gram negative bacteria including antibiotic resistant superbugs. Following regulatory requirements for new antibiotics, safety and efficacy tests will continue to urgently explore Recce® 327’s ability to address the global threat posed by superbugs. Together we can make antibiotic resistance history – visit recce.com.au to find out more.

Sign up for news and updates

Receive news and information direct to your inbox.